Bruce Power is announcing a new agreement with Isogen, BWXT to produce more 'Made in Ontario' life-saving isotopes.
A media release says today, Bruce Power, with Isogen and BWXT ITG Canada, Inc. signed a Memorandum of Understanding (MOU) to advance feasibility work for the production of Molybdenum-99 (Mo-99).
Mo-99 is the isotope most commonly used in nuclear medicine for diagnostic imaging and detection of disease and other isotopes in growing demand.
The partnership will work to leverage existing production systems being developed to produce Lutetium-177 (Lu-177) starting in 2022 at Bruce Power and BWXT's isotope-processing facilities in Kanata, ON, along with Kinectrics' facilities in Teeswater and Etobicoke.
The organizations also plan to complete an assessment of future isotope processing in Grey, Bruce and Huron counties to leverage the geographic proximity to the Bruce Power site to supply domestic and international needs.
Isogen is a joint venture between Framatome and Kinectrics, that aims to develop the use of CANDU reactors to produce the medical isotopes.
BWXT Canada designs, manufactures, commissions and services nuclear power generation equipment.